We are now engaged in a Phase 2b/3 clinical trial. A Phase 2a trial in moderate to severe plaque psoriasis patients began in January 2016. Further positive data was reported in September 2016. The SSR will be conducted when 50% of the patients have completed 18 months of therapy. Also, NASH non-invasive biomarkers will be evaluated. The tolerance and safety of belapectin will be evaluated. Therefore, there is a great need for other therapeutic options. There are no approved therapies for treatment of liver fibrosis. The IND was approved by FDA in February 2014. The patent, assigned U.S. Patent No. 8,828,971, was issued September 9, 2014. Applications are pending in multiple countries to extend patent protection globally. The Company's website is www.galectintherapeutics.com. We are a development stage company and have not generated any revenues to date. Obtaining FDA approval is a lengthy, expensive and uncertain process. Our lack of operating experience may cause us difficulty in managing our growth. In addition, data is susceptible to varying interpretations.
